EMA: parent whenever possible [Regulatives / Guidelines]

posted by cr.maroj – UK, 2013-09-20 12:14 (4662 d 04:37 ago) – Posting: # 11529
Views: 32,240

Dear Helmut,

❝ Spironolactone was problematic in the past, nowadays doable. Prodrug or not. Sorry for the confusion.


So, do you recommend analysing both Spironolactone and the metabolites? If so, BE criteria (for MHRA) will be based on parent or both?

Thank you,
Kind regards,
CR

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
231 visitors (0 registered, 231 guests [including 10 identified bots]).
Forum time: 16:51 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5